Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
LONDON, May 12, 2020 -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and.
LONDON, March 20, 2020 -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing.
LONDON, Feb. 21, 2020 -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces.
LONDON, Jan. 28, 2020 -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces.
LONDON, April 16, 2020 -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing.
LONDON, March 05, 2020 -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and.
Dr. David Zaccardelli appointed President and Chief Executive Officer Mark W. Hahn appointed Chief Financial Officer LONDON, Feb. 03, 2020 -- Verona Pharma plc (AIM: VRP).
LONDON, March 16, 2020 -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing.
The study met its primary endpoint demonstrating that ensifentrine produced clinically and statistically significant improvements in lung function at all doses. Also, clinically relevant secondary endpoints were met including significant progressive improvements in COPD symptoms.
The response supports Verona Pharma progressing with its planned Phase 3 clinical program, which is expected to start later in 2020. It is planned to be called the ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) program.
Analysis supports ensifentrine’s efficacy in COPD as monotherapy and on top of standard of care treatment in patients who remain symptomatic Six abstracts accepted.
LONDON, April 08, 2020 -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and.
As of late, it has definitely been a great time to be an investor Verona Pharma
LONDON, Feb. 07, 2020 -- TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft.
Abeona (ABEO) treats first patient in a pivotal study evaluating its gene-corrected cell therapy, EB-101, as a treatment for recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder.
Post-period end, reported positive top-line Phase 2b results with nebulized ensifentrine and senior management changes Conference Call Today at 9:00 am EST / 2:00 pm GMT.
Statistically significant and clinically meaningful improvements in lung function Ensifentrine has now demonstrated positive efficacy and safety in COPD patients via three.
Reported positive Phase 2b results in symptomatic patients with moderate to severe COPD with nebulized ensifentrine Reported positive efficacy and safety with single dose pMDI.
LONDON, April 23, 2020 -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces.